# OnCo record palbociclib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/palbociclib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "palbociclib" ;
  schema:name "Palbociclib"@en ;
  schema:description "Palbociclib was the first CDK4/6 inhibitor (2015), and in 2026 became the first approved as maintenance in HER2-positive, hormone-positive breast cancer."@en ;
  schema:url <https://onco.cc/drugs/palbociclib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Palbociclib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q15269707> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Palbociclib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule CDK4/6 inhibitor" ;
  schema:alternateName "Ibrance" ;
  onco:approval "US 2015: HR+/HER2- advanced breast cancer with endocrine therapy", "US 2026: HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy" ;
  onco:acceleratedApproval "US 2015-02-03: In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease" ;
  onco:acceleratedApprovalConfirmed "US 2017-03-31: In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease" ;
  onco:related <https://onco.cc/biomarkers/pr-status/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct03709680/>, <https://onco.cc/trials/nct05468697/>, <https://onco.cc/trials/nct04553133/>, <https://onco.cc/trials/nct04606446/>, <https://onco.cc/trials/nct05867251/>, <https://onco.cc/trials/nct04567420/>, <https://onco.cc/trials/nct05501886/>, <https://onco.cc/trials/nct05768139/>, <https://onco.cc/trials/nct06065748/>, <https://onco.cc/trials/nct06736704/>, <https://onco.cc/trials/nct07002177/>, <https://onco.cc/trials/nct05563220/>, <https://onco.cc/trials/nct04711252/>, <https://onco.cc/trials/nct06757634/>, <https://onco.cc/trials/nct04862663/>, <https://onco.cc/trials/nct05909397/>, <https://onco.cc/trials/nct06380751/>, <https://onco.cc/trials/nct06760637/>, <https://onco.cc/trials/nct05226871/> ;
  onco:people <https://onco.cc/people/massimo-cristofanilli/> .